Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Rosuvastatin and Metformin With or Without Calderasib in Healthy Participants
NCT07222098Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of calderasib (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity at 72 hours and Maximum Plasma Concentration at 120 hours. Started Nov 2025; status: completed.
02
Drugs
calderasib
Beyond the preview
Go deeper on NCT07222098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222098.